Navigation Links
Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
Date:3/26/2009

programs, and ability to develop novel medicines in the areas of hepatitis C and oncology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... results for the three months ended March 31, 2015 ... amounts are in Canadian dollars. Effective ... end from May 31 to December 31. As a ... reported is for the three months ended March 31, ...
(Date:5/5/2015)... DUBLIN , May 05, 2015 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. Macromolecules ... acids undergo separation or are broken into ... biotechnological products. This separation requires various advanced ...
(Date:5/5/2015)... , May 5, 2015 Reprints Desk, ... in providing on-demand access to scientific, technical and medical ... with the Association of Southeastern Research Libraries (ASERL) ... research libraries located across 11 southeastern states. Founded in ... and collaborative programs to address the continually changing needs ...
(Date:5/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ) ... Laboratory, Molecular Diagnostics and Genomic Testing Services Market ... Version" report to their offering. ... molecular diagnostics and pharmacogenics hold the promise of ... is moving out of the national and regional ...
Breaking Biology Technology:Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... Live Webcast from the Palace Hotel in San Francisco on Wednesday, ... ... 10th, SAN DIEGO, Oct. 2 Favrille, Inc. (Nasdaq:,FVRL), ... today announced that Tamara,Seymour, Chief Financial Officer, will present at the ...
... 454 Life Sciences, a Roche,company, and Perlegen Sciences, ... genetic re-sequencing in hundreds of DNA samples,collected by ... widely,prescribed class of drug. The goal of the ... can be identified and,validated to create a clinical ...
... SAFC(R), a member of the,Sigma-Aldrich(TM) Group (Nasdaq: ... to begin,construction of a new cGMP potent ... Pharma sector,s St. Louis manufacturing campus.,This addition ... requirements,that demand a combination of small molecule ...
Cached Biology Technology:New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 2New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 3SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite 2SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite 3
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... certain materials, researchers have grown carbon nanotubes that are ... than 2 centimeters long, each nanotube is 900,000 times ... potential to be longer, stronger and better conductors of ... use in smart fabrics, sensors and a host of ...
... An international team, led by researchers at the Broad ... National Institutes of Health (NIH), today announced the publication ... a South American species of opossum. In a comparison ... human, published in the May 10 issue of the ...
... of tissue-engineered scaffolding made of cartilage cells, which have ... cartilage tissue. Cartilage cells are extracted and seeded to ... new cartilage tissue is grown along the structure. The ... procedure was extremely successful in tested mice as the ...
Cached Biology News:The longest carbon nanotubes you've ever seen 2Researchers publish first marsupial genome sequence 2Researchers publish first marsupial genome sequence 3
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Myt 1 (N-17)...
... are functionally defined by their capacity to ... into multiple specialized progenitor cells, which can ... Neural stem cells (NSCs) are capable of ... neurons and oligodendrocytes. During the isolation and ...
Biology Products: